688658 悦康药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.3114.8788.47214.53318.810
总资产报酬率 ROA (%)2.0153.1015.7129.7529.909
投入资产回报率 ROIC (%)2.6964.1527.54613.01211.001

边际利润分析
销售毛利率 (%)58.30462.67164.64569.24266.015
营业利润率 (%)7.4205.5237.88112.82411.343
息税前利润/营业总收入 (%)7.1535.0766.97612.00612.323
净利润/营业总收入 (%)6.0484.4687.46210.95010.224

收益指标分析
经营活动净收益/利润总额(%)104.860105.69099.087103.01992.327
价值变动净收益/利润总额(%)0.000-0.4511.1380.6410.000
营业外收支净额/利润总额(%)-4.444-3.800-2.407-1.2000.603

偿债能力分析
流动比率 (X)1.8191.6032.0542.4172.188
速动比率 (X)1.4001.2621.6652.0411.835
资产负债率 (%)38.83939.13933.47431.42634.288
带息债务/全部投入资本 (%)17.74013.63010.9355.554--
股东权益/带息债务 (%)447.621612.764792.2251,651.120833.064
股东权益/负债合计 (%)157.072155.074198.333218.025191.380
利息保障倍数 (X)147.895-20.734-9.695-18.02913.512

营运能力分析
应收账款周转天数 (天)76.10391.00781.03250.0780.000
存货周转天数 (天)165.131168.463153.642148.3640.000